Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy
- PMID: 37951841
- DOI: 10.1210/endocr/bqad166
Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy
Abstract
Recently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.
Keywords: GIP; GLP-1; coagonists; glucagon; obesity; type 2 diabetes.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Comment on
-
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases.Endocrinology. 2023 Sep 23;164(11):bqad153. doi: 10.1210/endocr/bqad153. Endocrinology. 2023. PMID: 37823483 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
